November 21, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Carna Biosciences and CrystalGenomics to Collaborate in Drug Candidate Development
 

Tokyo, June 10, 2004 (JCN) - Carna Biosciences announced on June 9 that it has agreed with Korean pharmaceutical company CrystalGenomics to collaborate in the field of drug discovery.

Under this partnership, the two companies will jointly research and develop candidate compounds for new drugs by making full use of each's expertise.

The two companies will focus on the treatments of cancer, articular rheumatism and atherosclerosis.

By Aki Tsukioka Contributor

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Carna Biosciences Inc. News  
  Carna Biosciences, Enamine to Collaborate in Research on Kinase  (May 18, 2006)
  Carna Biosciences, Enamine to Collaborate in Research on Kinase  (May 18, 2006)
  Carna Biosciences, ChemDiv to Collaborate in Creating and Marketing Annotated Kinase-focused Library  (Mar 31, 2006)
  Ginkgo Biomedical Research Institute, Carna Biosciences, CrystalGenomics to Collaborate in New Cancer Drug Development  (Mar 16, 2006)
  Carna Biosciences, CrystalGenomics, Rigel Pharmaceuticals Sign Service Agreement for X-ray Crystal Structure Analysis  (June 22, 2005)
  Fujirebio, Carna Biosciences to Co-develop Kinase Assay-related Products  (Oct 6, 2004)
  Carna Biosciences and CrystalGenomics to Collaborate in Drug Candidate Development  (June 10, 2004)
  Myristoyl Protein Directly Linked to Protein-protein Interaction: Riken and Carna Biosciences  (Feb 16, 2004)



 Recent  Drugs & OTC News   
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)

More Drugs & OTC news...

 Recent  Drugs & OTC News   
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)